Format

Send to

Choose Destination
Br J Cancer. 2018 Jul;119(2):193-199. doi: 10.1038/s41416-018-0168-9. Epub 2018 Jul 5.

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

Author information

1
Department of Pathology, Hôpital Haut-Lévêque (CHU de Bordeaux), 33604, Pessac, France.
2
Department of Pathology, Oncopole de Toulouse, 31100, Toulouse, France.
3
Université Paul-Sabatier, 31400, Toulouse, France.
4
Department of Dermatology, Hôpital Saint-André (CHU de Bordeaux), 33000, Bordeaux, France.
5
Department of Dermatology, Paul-Sabatier-Toulouse III University (CHU de Toulouse), 31059, Toulouse, France.
6
Department of Biostatistics, Oncopole de Toulouse, 31100, Toulouse, France.
7
INSERM U1053 Team 1 (université de Bordeaux), 33076, Bordeaux, France.
8
Department of Tumour Biology and Tumour Bank, Hôpital Haut-Lévêque (CHU de Bordeaux), 33604, Pessac, France.
9
Department of Pathology, Hôpital Haut-Lévêque (CHU de Bordeaux), 33604, Pessac, France. beatrice.vergier@chu-bordeaux.fr.
10
INSERM U1053 Team 1 (université de Bordeaux), 33076, Bordeaux, France. beatrice.vergier@chu-bordeaux.fr.

Abstract

BACKGROUND:

Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status is technically challenging and is not mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive of a response to anti-PD-1 therapy could contribute to improving therapeutic decision-making.

METHODS:

This retrospective study on 70 metastatic melanoma patients was undertaken to evaluate the relationships between clinical, histological, immunohistochemical and/or molecular criteria, and the 6-month objective response rate.

RESULTS:

Better objective response rates were associated with metachronous metastases (P = 0.04), PD-L1 tumour- and/or immune-cell status (P = 0.01), CD163+ histiocytes at advancing edges (P = 0.009) of primary melanomas and NRAS mutation (P = 0.019). Moreover, CD163+ histiocytes at advancing edges (P = 0.04) were associated with longer progression-free survival (PFS), and metachronous metastases with longer overall survival (P = 0.02) and PFS (P = 0.049).

CONCLUSIONS:

Combining these reproducible biomarkers could help improve therapeutic decision-making for patients with progressive disease.

PMID:
29973670
PMCID:
PMC6048096
[Available on 2019-07-17]
DOI:
10.1038/s41416-018-0168-9

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center